Jianfeng Group announced that its subsidiary has obtained a notice of approval for the marketing application of imatinib mesylate as a chemical raw material. Imatinib mesylate is the mesylate salt of imatinib, a tyrosine kinase inhibitor with antitumor activity.
尖峰集团：子公司获得甲磺酸伊马替尼化学原料药上市申请批准通知书
Jianfeng Group: The subsidiary obtained a notice of approval for the marketing application of imatinib mesylate as a chemical raw material
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.